New Stents, New Procedures, and Intraprocedural Challenges

  • Annapoorna Kini
  • Jagat Narula
  • Yuliya Vengrenyuk
  • Samin Sharma


Bioresorbable vascular scaffolds (BRSs) have recently reenergized the field of coronary intervention; they support transient drug delivery and vessel patency and then gradually tend to complete resorption. OCT has played a major role in the development of BRS technology by providing more precise and detailed morphologic information (compared to IVUS) as a result of its higher resolution. While the clinical outcome data from the landmark BRS trials are promising, there is a paucity of data on BRS implantation in unselected patient population in “real world” clinical practice, including in-stent restenosis, bifurcation, and severely calcified lesions. Abnormal coronary dilatation at the site of DES implantation demonstrating contrast staining outside the stent struts, peri-stent contrast staining (PSS), have been shown to be associated with target-lesion revascularization and very late stent thrombosis. OCT can differentiate between two main underlying causes of PSS, incomplete stent apposition and multiple interstrut hollows or cavities between well apposed stent struts. Intraluminal filling defects are occasionally observed on coronary angiography, and thrombosis has often been used as a default diagnosis; however, there are many different causes responsible for the phenomenon including calcification, dissection, plaque rupture, and artifacts. OCT allows accurate characterization angiographic filling defects and provides important information for treatment optimization.


Drug-eluting stents Bare metal stents Stent thrombosis Bioresorbable vascular scaffolds Peri-stent contrast staining Intraluminal filling defects Thrombosis Calcified lesion Dissection In-stent restenosis Lipid-rich plaque Thin fibrous cap Stent edge dissection Healed plaque rupture 

Supplementary material

Video 5.1

OCT pullback after rotational atherectomy for heavily calcified LAD lesions (Case 1, Fig. 5.1, B1–B4, C) (AVI 16764 kb)

Video 5.2

OCT pullback performed after implantation of two bioresorbable vascular scaffolds (Case 1, Fig. 5.2, B1–B5, C) (AVI 23382 kb)

Video 5.3

OCT pullback performed after chronic total occlusion was crossed and orbital atherectomy performed for the calcified lesion (Case 2, Fig. 5.3, B1–B7, C) (AVI 21623 kb)

Video 5.4

OCT pullback of the chronic total occlusion after bioresorbable vascular scaffold implantation (Case 2, Fig. 5.4, B1–B5, C) (AVI 22870 kb)

Video 5.5

OCT pullback for the case of late stent malapposition with total occlusion of the stent (Explaining the unexplainable) (Case 3, Fig. 5.5, B1–B8, C) (AVI 20794 kb)

Video 5.6

OCT pullback before stenting for an intermediate stenosis with intraluminal filling defect in the proximal LAD, Clarifying the halos (Case 4, Fig. 5.6, B1–B4, C1, C2) (AVI 19666 kb)

Video 5.7

Post-stent OCT for the “Clarifying the halos” case (Case 4, Fig. 5.7, B1, B2, C1, C2) (AVI 19438 kb)

Video 5.8

OCT pullback before stenting mid LAD stenosis (Case 5, Fig. 5.8, B1–B5, C) (AVI 22121 kb)

Video 5.9

OCT performed after mid LAD stenting showed new thrombus in the proximal LAD (Case 5, Fig. 5.9, B1–B5, C) (AVI 22216 kb)

Video 5.10

Final post-PCI OCT pullback after proximal LAD noncompliant balloon post-dilatation (Case 5, Fig. 5.10, B1–B5, C) (AVI 22088 kb)


  1. 1.
    Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J. 2012;33:16–25b.CrossRefPubMedGoogle Scholar
  2. 2.
    Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol. 2006;18:70–4.PubMedGoogle Scholar
  3. 3.
    Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J. 2012;33:1325–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Okamura T, Serruys PW, Regar E. Cardiovascular flashlight. The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. Eur Heart J. 2010;31:2179.CrossRefPubMedGoogle Scholar
  5. 5.
    Gomez-Lara J, Brugaletta S, Farooq V, Onuma Y, Diletti R, Windecker S, et al. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv. 2011;4:1271–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Karanasos A, Simsek C, Gnanadesigan M, Nienke S, van Ditzhuijzen MSC, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2014;64:2343–56.CrossRefPubMedGoogle Scholar
  7. 7.
    Mattesini A, Secco GG, Dall’Ara G, Ghione M, Rama-Merchan JC, Lupi A, et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv. 2014;7:741–50.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhang YJ, Iqbal J, Nakatani S, Bourantas CV, Campos C, Ishibashi Y, et al. Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study. JACC Cardiovasc Interv. 2014;7:1361–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58:1578–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Diletti R, Serruys PW, Farooq V, Sudhir K, Dorange C, Miquel-Sudhir K, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012;164:654–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905–15.CrossRefPubMedGoogle Scholar
  12. 12.
    Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144–53.CrossRefPubMedGoogle Scholar
  13. 13.
    Kawamoto H, Ruparelia N, Figini F, Latib A, Colombo A. Severe neointimal hyperplasia of neoplastic carina following bioresorbable scaffold implantation using t-stenting and small protrusion technique: insights from optical frequency domain imaging. JACC Cardiovasc Interv. 2015;8:e207–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Capranzano P, Francaviglia B, Capodanno D, Di Salvo ME, Tamburino CI, Santagati FM, et al. Embolization of fractured bioresorbable scaffold struts: insights from 2- and 3-dimensional optical coherence tomography. JACC Cardiovasc Interv. 2016;9:e37–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Karanasos A, Van Mieghem N, van Ditzhuijzen N, Felix C, Daemen J, Autar A, et al. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv. 2015;8(5). pii: e002369. doi:  10.1161/CIRCINTERVENTIONS.114.002369.
  16. 16.
    Imai M, Kadota K, Goto T, Fujii S, Yamamoto H, Fuku Y, et al. Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation. 2011;123:2382–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Tada T, Kadota K, Hosogi S, Kubo S, Ozaki M, Yoshino M, et al. Optical coherence tomography findings in lesions after sirolimus-eluting stent implantation with peri-stent contrast staining. Circ Cardiovasc Interv. 2012;5:649–56.CrossRefPubMedGoogle Scholar
  18. 18.
    Jaffe R, Irfan A, Hong T, Chisholm RJ, Cheema AN. Intraluminal filling defects on coronary angiography: more than meets the eye. Clin Cardiol. 2007;30:480–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Annapoorna Kini
    • 1
  • Jagat Narula
    • 2
  • Yuliya Vengrenyuk
    • 3
  • Samin Sharma
    • 4
  1. 1.Director, Cardiac Catheterization Laboratory, Director, Structural Heart Intervention Program, Director, Interventional Cardiology Fellowship Program, Zena and Michael A. Wiener Professor of MedicineIcahn School of Medicine at Mount Sinai, Mount Sinai HospitalNew YorkUSA
  2. 2.Director, Intravascular Imaging Core Laboratory, Instructor, Department of MedicineIcahn School of Medicine at Mount Sinai, Mount Sinai HospitalNew YorkUSA
  3. 3.Philip J. and Harriet L. Goodhart Chair in Cardiology, Chief of Cardiology, Mount Sinai St. Luke’s Hospital, Professor of Medicine and Radiology, Associate Dean, Arnhold Institute for Global HealthIcahn School of Medicine at Mount Sinai, Mount Sinai HospitalNew YorkUSA
  4. 4.Director, Clinical and Interventional Cardiology, President, Mount Sinai Heart Network, Dean, International Clinical Affiliations, Anandi Lal Sharma Professor of MedicineIcahn School of Medicine at Mount Sinai, Mount Sinai HospitalNew YorkUSA

Personalised recommendations